Physics Informed Machine Learning-based Prediction and Reversion of Impaired Fasting Glucose Management
Sponsor: Jelizaveta Sokolovska
Trial Details
| Condition | Prediabetic State, Body Weight, Overweight or Obesity, Life Style, Healthy |
| Status | Completed |
| Participants | 77 |
| Est. Completion | 30 Sept 2025 |
| Last Updated | 6 May 2026 |
Primary Outcome
Validation of the Mission T2D (MT2D) algorithm outputs, that predicts the real time risk for developing pre-diabetes.
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Healthy adult volunteers (age ≥ 18 years old); * Overweight (BMI 25 - 29.9 kg/m2) and obese grade I individuals (with BMI 30 - 34.9 kg/m2); * Written consent of the participant after being informed; * Ownership of a smartphone running Android or iOS. Exclusion Criteria: * Non-compliance; * Ongoing treatment with immunosuppressive and/or anti-inflammatory medications (NSAIDs, glucocorticoids, chemotherapy, biologicals); * Ongoing treatment with glucose lowering drugs, except if anti-diabetic medication has not been stopped - for metformin one month, for GLP-1 RA, tirzepatide - two months prior enrolment; * Presence of autoimmune and/or inflammatory disease (autoimmune thyroid disease, psoriasis, inflammatory bowel disease); * Skin conditions hindering application of continuous glucose monitoring systems; * Diabetes or prediabetes as diagnosed by ADA/WHO criteria according to fasting glucose and/or HbA1c; * High risk alcohol consumption - according to NIAAA - National Institute on Alcohol Abuse and Alcoholism (for men - more than 4 drinks on any day or more than 14 drinks per week; for women - more than 3 drinks on any day or more than 7 drinks per week); * Factors otherwise limiting the participation in the study according to the judgement of the investigator; * Pregnancy or intention to get pregnant during the study timeline.
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service